Clinical Trial Update: A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI [Phase 2]

View source ↗

Summary

Phase 2 dose titration study evaluating SAR407899 in patients with microvascular coronary artery disease; the trial was terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Microvascular Coronary Artery Disease

Drugs mentioned

• SAR407899

Snippet

Sponsor: Sanofi | Conditions: Microvascular Coronary Artery Disease | Phase 2 | Status: TERMINATED | Results posted: 2019-07-11